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A B S T R A C T
Alemtuzumab, a highly eﬀective treatment for relapsing remitting multiple sclerosis (RRMS), induces lympho-
penia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients
with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count de-
creased and ﬂuctuated accordingly to alemtuzumab administration, their CD4+ cell percentage was not or just
mildly aﬀected and was slightly below the lowest normal limit already before alemtuzumab. These cases an-
ticipate further studies aimed to investigate whether the evaluation of the CD4+ cell percentage could represent
a helpful tool to address the individual clinical response to alemtuzumab.
1. Introduction
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody
that selectively targets the CD52 antigen, expressed mainly on T and B
lymphocytes and, at lower levels, on natural killer, monocytes and
dendritic cells (Turner et al., 2013; Hartung et al., 2015). In two phase 3
clinical trials (Comparison of Alemtuzumab and Rebif Eﬃcacy in
Multiple Sclerosis - CARE-MS I and CARE-MS II) (Cohen et al., 2012;
Coles et al., 2012) in relapsing remitting multiple sclerosis (RRMS)
patients, alemtuzumab resulted more eﬀective than interferon beta-1a
(IFN beta-1a) in reducing relapses and brain volume loss. Alemtuzumab
induces a profound and prolonged lymphopenia especially of the
CD4+ population (Cossburn et al., 2013). The depletion of CD4+ cells
usually lasts for years, but an accelerated CD4+ recovery was asso-
ciated with an early return of disease activity (Cossburn et al., 2013).
2. Cases
Here we report the atypical immunological features of two RRMS
patients who presented a sustained disease activity despite
alemtuzumab treatment. These patients belong to the cohort of 29
alemtuzumab treated patients from CARE-MS I and CARE-MS II trials of
our previous (De Mercanti et al., 2016) and ongoing studies (Durelli
et al., 2016). Patients were neurologically evaluated at baseline and
then every 6 months or in case of relapses. Immunological studies were
performed at baseline and every 6 months during the ﬁrst 24 months
and every 12 months thereafter.
Patient number 1 (P#1) is a 36 years old woman, diagnosed with
RRMS in 2000, initially treated with IFN beta-1a, who developed a
sustained disease activity with 4 relapses in the two years preceding
alemtuzumab administration. The ﬁrst alemtuzumab course (5 days)
was given in July 2009; before alemtuzumab treatment the patient had
an EDSS (Expanded Disability Status Scale) (Kurtzke, 1983) score of
2.0. After 12 months the second alemtuzumab course (3 days) was ad-
ministered and patient EDSS was 1. In June 2012 and in February 2013
the patient had two relapses, with an increase of EDSS score to 2.5 and
3, respectively, both treated with intravenous (iv) methylprednisolone
1000 mg/day for 3 days and a subsequent return to the pre-relapses
condition of EDSS 1. After the second relapse, on February 2013, a
further 3-day alemtuzumab course was given. In August 2015, the
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patient had unique MRI activity without clinical signs of relapse and
EDSS 1. In August 2016 the patient presented both new enhancing le-
sions at MRI as well as clinical manifestation of relapse with EDSS 3.
The patient did not recover from the relapse as the EDSS was still 3 and
in October 2016 she received a further 3-day alemtuzumab course
(Fig. 1).
Patient number 2(P#2) is a 27 years old female, diagnosed with
RRMS in 2008; she was treated with IFN beta-1a from 2008 to 2009 and
had 2 relapses on January and April 2009; in July 2009 she was ran-
domised in the IFN beta-1a branch and was clinically stable for two
years with an EDSS score of 1.5. She was then switched to alemtuzumab
in the extension phase of the CARE-MS II study and received the ﬁrst
alemtuzumab course (5 days) in August 2011. In August 2012 she re-
ceived the second alemtuzumab course (3 days). The patient had a re-
lapse in August 2013 with an EDSS increase to 2.0; she received a
further 3-day alemtuzumab course and in January 2014 her EDSS went
down to 1.5. In October 2013 she became unexpectedly pregnant and
had delivered in July 2014. In the post-partum period (October 2014)
she had a clinical relapse, treated with iv methylprednisolone 1000 mg/
day for 3 days. In January 2015 she received a further 3-day alemtu-
zumab course. In October 2015 and August 2016 the patient had two
more clinical relapses, associated with evidence of new enhancing le-
sions at MRI and with an EDSS increase to 3.5. In December 2016 the
patient EDSS was 1.5 and she started ﬁngolimod therapy. Both patients
did not developed any autoimmune side eﬀects.
These patients display a peculiar behaviour of CD4+ population
associated with sustained clinical and radiological disease activity de-
spite repeated alemtuzumab courses. Fig. 1 reports the immunological
reconstitution in terms of lymphocytes count and CD4+ T cell per-
centage in both patients and in the other 27 patients of our cohort that
responded to alemtuzumab treatment (responder patients). Six months
after the ﬁrst alemtuzumab course the lymphocytes count was still
strongly decreased in both patients: from 1752/μl to 427/μl in P#1 and
from 1682/μl to 530/μl inP#2. By contrast the percentage of CD4+ T
cells was marginally aﬀected or showed a mild increase in P#1 (from
24.8% to 28.2%). Lymphocyte count then recovered to normal values
around Month 24, as in the responder patients, and ﬂuctuated ac-
cordingly to alemtuzumab administration, thereafter. In P#1, the per-
centage of CD4+ T cells, starting below the lowest normal limit (LNL)
at baseline, did not change signiﬁcantly and remained always below
LNL with the exception of Month 72 when showed a slight increase
during an MRI relapse. In P#2 the percentage of CD4+ T cells, starting
just below LNL at baseline, increased at month 24 in concomitance with
a relapse, decreased a little after the third alemtuzumab course, and
then remained unchanged.
3. Discussion
One of the main challenges in the research on MS is the identiﬁ-
cation of biomarkers detectable in the biological ﬂuids, especially
blood, that could easily identify the response to therapy and guide
patient management reliably. In this context, lymphocytes count and
their immunological proﬁle seems to act as response predictors to
second line drugs in which risks and beneﬁts should be carefully ba-
lanced: recently, it was observed that lymphocytes subpopulation eva-
luation might predict the risk of clinical and radiological activities in
ﬁngolimod treated patients (Paolicelli et al., 2017) and that lympho-
cytosis could be a biomarker of therapeutic eﬃcacy in natalizumab
treated patients (Signoriello et al., 2016). Cossburn et al. (Cossburn
et al., 2013) reported, in 56 RRMS alemtuzumab treated patients fol-
lowed for a median of 39.5 months, that relapse-free patients had a
signiﬁcant lower CD4+ lymphocyte count from 6 months after treat-
ment until the end of the study period compared to patients with one or
more relapses. Similarly, our case report on the long lasting behaviour
of the CD4+ T cells subset in alemtuzumab treated patients shows two
patients (followed for 5 and 7.5 years from starting alemtuzumab) with
almost unchanged T CD4+ percentage from baseline despite the re-
peated alemtuzumab administrations needed for clinical and radi-
ological relapses. In our study cohort (De Mercanti et al., 2016; Durelli
et al., 2016) alemtuzumab administration strongly aﬀected the per-
centage of CD4+ cells: it was reduced by 66% at Month 6 and by 51%
at Month 12 and then slowly increased returning to baseline around
Month 48 (Fig. 1). By contrast, the CD4+ population of these 2 patients
seems not aﬀected by alemtuzumab. The CD52 diﬀerent expression in
CD4+ T cell (Bandala-Sanchez et al., 2013) might explain why some
patients do not show a CD4+ T cell decrease after alemtuzumab. In
addition, the CD4+ T cell percentage was below LNL already before
alemtuzumab in those two patients. It could be possible that they had
Fig. 1. Eﬀect of alemtuzumab on lymphocyte count (upper panels) and CD4+ T cell percentage (lower panels) in two non-responder (P#1 and P#2) and in 27 responder patients
(mean ± SD). Dotted vertical lines indicate alemtuzumab courses, black arrows indicate the clinical and/or radiological relapses during the follow-up. The horizontal lines are the lowest
normal limit (LNL).
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CD4+ T cells already suppressed by preceding treatment with IFN
beta-1a; one of the eﬀects of IFNβ is indeed the impairment of lym-
phocytes egression from the lymphnodes (Shiow et al., 2006); CD4+ T
cells could remain concealed from the usual therapeutic eﬀects of
alemtuzuamb as it was hypothesized in patients who developed un-
expected disease activity during alemtuzuamb treatment after ﬁngo-
limod discontinuation (Willis et al., 2017). These patients might so
require a treatment with a drug that preferentially aﬀects B rather than
T cells, or a better strategy for the therapeutic switch. Based on the
small sample size, deﬁnitive conclusions cannot be drawn and further
analyses are needed. If our results will be conﬁrmed in a higher number
of patients, the evaluation of the CD4+ T cells percentage, before and
after alemtuzumab treatment, could become a helpful tool to predict
clinical response to the drug, in order to better address the therapeutic
choice.
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